Starpharma Hldgs S/Adr

7.6500-0.0800-1.03%Vol 3.29K1Y Perf -22.49%
Nov 26th, 2021 11:52
BID0.0000 ASK0.0000
Open7.7100 Previous Close7.7300
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     56.11
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.17 
Earnings Rating
Market Cap311.11M 
Earnings Date
-
Alpha-0.00 Standard Deviation0.16
Beta1.55 

Today's Price Range

7.65007.7100

52W Range

7.250019.870

5 Year PE Ratio Range

-32.10078.200

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
5.52%
1 Month
-4.20%
3 Months
-10.00%
6 Months
-42.37%
1 Year
-22.49%
3 Years
-29.62%
5 Years
52.13%
10 Years
0.00%

TickerPriceChg.Chg.%
SPHRY7.6500-0.0800-1.03
AAPL156.81-5.1300-3.17
GOOG2 856.12-78.2300-2.67
MSFT329.68-8.2300-2.44
XOM61.25-2.2300-3.51
WFC48.43-2.8800-5.61
JNJ159.20-1.0400-0.65
FB333.12-7.9400-2.33
GE97.84-4.3900-4.29
JPM161.93-5.0300-3.01
Financial StrengthValueIndustryS&P 500US Markets
6.60
6.80
0.01
0.02
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
56.00
-1 863.80
-1 863.80
-596.50
-
RevenueValueIndustryS&P 500US Markets
1.30M
0.03
-8.21
-5.92
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume3.29K
Shares Outstanding40.67M
Shares Float40.67M
Trades Count7
Dollar Volume25.25K
Avg. Volume2.70K
Avg. Weekly Volume2.14K
Avg. Monthly Volume1.80K
Avg. Quarterly Volume2.03K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Starpharma Hldgs S/Adr

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialisation of dendrimer products for a pharmaceutical, life-science and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis, and as a condom coating.

CEO:

Telephone: +61 385322700

Address: 4-6 Southampton Crescent, Melbourne 3067, VIC, AUS

Number of employees: 0

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

40%60%

Bearish Bullish

56%44%

News